PMC:7417114 / 57223-57973 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T279","span":{"begin":235,"end":241},"obj":"Body_part"},{"id":"T280","span":{"begin":366,"end":370},"obj":"Body_part"},{"id":"T281","span":{"begin":573,"end":577},"obj":"Body_part"},{"id":"T282","span":{"begin":732,"end":736},"obj":"Body_part"}],"attributes":[{"id":"A279","pred":"fma_id","subj":"T279","obj":"http://purl.org/sig/ont/fma/fma9637"},{"id":"A280","pred":"fma_id","subj":"T280","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A281","pred":"fma_id","subj":"T281","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A282","pred":"fma_id","subj":"T282","obj":"http://purl.org/sig/ont/fma/fma7195"}],"text":"Crizotinib (Xalkori)\n(Pfizer) High-fat meal decreases Cmax and AUC;\nCmax 4 to 6 h following oral dosing;\nM=Mean absolute bioavailability=43% after 250 mg oral dose;\nVd= 1772 L (after IV administration 50 mg) (suggests potentially high tissue distribution) Metabolized by CYP3A4, CYP3A5 250 mg orally twice daily;\n91% binding Pulmonary toxicity, such as interstitial lung disease, is a rare side effect associated with ALK inhibitors; most can be managed efficiently by lowering doses or interrupting treatment; crizotinib was responsible for adverse pulmonary interstitial lung disease and severe pneumonitis in a small percentage of patients (238) (239) (240); associated with ground-glass opacity predominant pattern interstitial lung disease (151)"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T87","span":{"begin":235,"end":241},"obj":"Body_part"},{"id":"T88","span":{"begin":366,"end":370},"obj":"Body_part"},{"id":"T89","span":{"begin":573,"end":577},"obj":"Body_part"},{"id":"T90","span":{"begin":732,"end":736},"obj":"Body_part"}],"attributes":[{"id":"A87","pred":"uberon_id","subj":"T87","obj":"http://purl.obolibrary.org/obo/UBERON_0000479"},{"id":"A88","pred":"uberon_id","subj":"T88","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A89","pred":"uberon_id","subj":"T89","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A90","pred":"uberon_id","subj":"T90","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"Crizotinib (Xalkori)\n(Pfizer) High-fat meal decreases Cmax and AUC;\nCmax 4 to 6 h following oral dosing;\nM=Mean absolute bioavailability=43% after 250 mg oral dose;\nVd= 1772 L (after IV administration 50 mg) (suggests potentially high tissue distribution) Metabolized by CYP3A4, CYP3A5 250 mg orally twice daily;\n91% binding Pulmonary toxicity, such as interstitial lung disease, is a rare side effect associated with ALK inhibitors; most can be managed efficiently by lowering doses or interrupting treatment; crizotinib was responsible for adverse pulmonary interstitial lung disease and severe pneumonitis in a small percentage of patients (238) (239) (240); associated with ground-glass opacity predominant pattern interstitial lung disease (151)"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T539","span":{"begin":353,"end":378},"obj":"Disease"},{"id":"T540","span":{"begin":366,"end":378},"obj":"Disease"},{"id":"T541","span":{"begin":560,"end":585},"obj":"Disease"},{"id":"T542","span":{"begin":573,"end":585},"obj":"Disease"},{"id":"T543","span":{"begin":597,"end":608},"obj":"Disease"},{"id":"T544","span":{"begin":719,"end":744},"obj":"Disease"},{"id":"T545","span":{"begin":732,"end":744},"obj":"Disease"}],"attributes":[{"id":"A539","pred":"mondo_id","subj":"T539","obj":"http://purl.obolibrary.org/obo/MONDO_0015925"},{"id":"A540","pred":"mondo_id","subj":"T540","obj":"http://purl.obolibrary.org/obo/MONDO_0005275"},{"id":"A541","pred":"mondo_id","subj":"T541","obj":"http://purl.obolibrary.org/obo/MONDO_0015925"},{"id":"A542","pred":"mondo_id","subj":"T542","obj":"http://purl.obolibrary.org/obo/MONDO_0005275"},{"id":"A543","pred":"mondo_id","subj":"T543","obj":"http://purl.obolibrary.org/obo/MONDO_0043905"},{"id":"A544","pred":"mondo_id","subj":"T544","obj":"http://purl.obolibrary.org/obo/MONDO_0015925"},{"id":"A545","pred":"mondo_id","subj":"T545","obj":"http://purl.obolibrary.org/obo/MONDO_0005275"}],"text":"Crizotinib (Xalkori)\n(Pfizer) High-fat meal decreases Cmax and AUC;\nCmax 4 to 6 h following oral dosing;\nM=Mean absolute bioavailability=43% after 250 mg oral dose;\nVd= 1772 L (after IV administration 50 mg) (suggests potentially high tissue distribution) Metabolized by CYP3A4, CYP3A5 250 mg orally twice daily;\n91% binding Pulmonary toxicity, such as interstitial lung disease, is a rare side effect associated with ALK inhibitors; most can be managed efficiently by lowering doses or interrupting treatment; crizotinib was responsible for adverse pulmonary interstitial lung disease and severe pneumonitis in a small percentage of patients (238) (239) (240); associated with ground-glass opacity predominant pattern interstitial lung disease (151)"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T639","span":{"begin":35,"end":38},"obj":"http://purl.obolibrary.org/obo/UBERON_0001013"},{"id":"T640","span":{"begin":366,"end":370},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T641","span":{"begin":366,"end":370},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T642","span":{"begin":383,"end":384},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T643","span":{"begin":573,"end":577},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T644","span":{"begin":573,"end":577},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T645","span":{"begin":612,"end":613},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T646","span":{"begin":732,"end":736},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T647","span":{"begin":732,"end":736},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"}],"text":"Crizotinib (Xalkori)\n(Pfizer) High-fat meal decreases Cmax and AUC;\nCmax 4 to 6 h following oral dosing;\nM=Mean absolute bioavailability=43% after 250 mg oral dose;\nVd= 1772 L (after IV administration 50 mg) (suggests potentially high tissue distribution) Metabolized by CYP3A4, CYP3A5 250 mg orally twice daily;\n91% binding Pulmonary toxicity, such as interstitial lung disease, is a rare side effect associated with ALK inhibitors; most can be managed efficiently by lowering doses or interrupting treatment; crizotinib was responsible for adverse pulmonary interstitial lung disease and severe pneumonitis in a small percentage of patients (238) (239) (240); associated with ground-glass opacity predominant pattern interstitial lung disease (151)"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T74312","span":{"begin":183,"end":185},"obj":"Chemical"},{"id":"T45971","span":{"begin":418,"end":432},"obj":"Chemical"},{"id":"T29042","span":{"begin":422,"end":432},"obj":"Chemical"},{"id":"T84846","span":{"begin":511,"end":521},"obj":"Chemical"}],"attributes":[{"id":"A92302","pred":"chebi_id","subj":"T74312","obj":"http://purl.obolibrary.org/obo/CHEBI_74327"},{"id":"A69024","pred":"chebi_id","subj":"T45971","obj":"http://purl.obolibrary.org/obo/CHEBI_62434"},{"id":"A27953","pred":"chebi_id","subj":"T29042","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A33153","pred":"chebi_id","subj":"T84846","obj":"http://purl.obolibrary.org/obo/CHEBI_64310"}],"text":"Crizotinib (Xalkori)\n(Pfizer) High-fat meal decreases Cmax and AUC;\nCmax 4 to 6 h following oral dosing;\nM=Mean absolute bioavailability=43% after 250 mg oral dose;\nVd= 1772 L (after IV administration 50 mg) (suggests potentially high tissue distribution) Metabolized by CYP3A4, CYP3A5 250 mg orally twice daily;\n91% binding Pulmonary toxicity, such as interstitial lung disease, is a rare side effect associated with ALK inhibitors; most can be managed efficiently by lowering doses or interrupting treatment; crizotinib was responsible for adverse pulmonary interstitial lung disease and severe pneumonitis in a small percentage of patients (238) (239) (240); associated with ground-glass opacity predominant pattern interstitial lung disease (151)"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1534","span":{"begin":271,"end":277},"obj":"Gene"},{"id":"1535","span":{"begin":279,"end":285},"obj":"Gene"},{"id":"1536","span":{"begin":418,"end":421},"obj":"Gene"},{"id":"1585","span":{"begin":634,"end":642},"obj":"Species"}],"attributes":[{"id":"A1534","pred":"tao:has_database_id","subj":"1534","obj":"Gene:1576"},{"id":"A1535","pred":"tao:has_database_id","subj":"1535","obj":"Gene:1577"},{"id":"A1536","pred":"tao:has_database_id","subj":"1536","obj":"Gene:238"},{"id":"A1585","pred":"tao:has_database_id","subj":"1585","obj":"Tax:9606"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Crizotinib (Xalkori)\n(Pfizer) High-fat meal decreases Cmax and AUC;\nCmax 4 to 6 h following oral dosing;\nM=Mean absolute bioavailability=43% after 250 mg oral dose;\nVd= 1772 L (after IV administration 50 mg) (suggests potentially high tissue distribution) Metabolized by CYP3A4, CYP3A5 250 mg orally twice daily;\n91% binding Pulmonary toxicity, such as interstitial lung disease, is a rare side effect associated with ALK inhibitors; most can be managed efficiently by lowering doses or interrupting treatment; crizotinib was responsible for adverse pulmonary interstitial lung disease and severe pneumonitis in a small percentage of patients (238) (239) (240); associated with ground-glass opacity predominant pattern interstitial lung disease (151)"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T164","span":{"begin":353,"end":378},"obj":"Phenotype"},{"id":"T165","span":{"begin":560,"end":585},"obj":"Phenotype"},{"id":"T166","span":{"begin":719,"end":744},"obj":"Phenotype"}],"attributes":[{"id":"A164","pred":"hp_id","subj":"T164","obj":"http://purl.obolibrary.org/obo/HP_0006530"},{"id":"A165","pred":"hp_id","subj":"T165","obj":"http://purl.obolibrary.org/obo/HP_0006530"},{"id":"A166","pred":"hp_id","subj":"T166","obj":"http://purl.obolibrary.org/obo/HP_0006530"}],"text":"Crizotinib (Xalkori)\n(Pfizer) High-fat meal decreases Cmax and AUC;\nCmax 4 to 6 h following oral dosing;\nM=Mean absolute bioavailability=43% after 250 mg oral dose;\nVd= 1772 L (after IV administration 50 mg) (suggests potentially high tissue distribution) Metabolized by CYP3A4, CYP3A5 250 mg orally twice daily;\n91% binding Pulmonary toxicity, such as interstitial lung disease, is a rare side effect associated with ALK inhibitors; most can be managed efficiently by lowering doses or interrupting treatment; crizotinib was responsible for adverse pulmonary interstitial lung disease and severe pneumonitis in a small percentage of patients (238) (239) (240); associated with ground-glass opacity predominant pattern interstitial lung disease (151)"}

{"project":"LitCovid-sentences","denotations":[{"id":"T476","span":{"begin":0,"end":20},"obj":"Sentence"},{"id":"T477","span":{"begin":21,"end":67},"obj":"Sentence"},{"id":"T478","span":{"begin":68,"end":104},"obj":"Sentence"},{"id":"T479","span":{"begin":105,"end":164},"obj":"Sentence"},{"id":"T480","span":{"begin":165,"end":312},"obj":"Sentence"},{"id":"T481","span":{"begin":313,"end":750},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Crizotinib (Xalkori)\n(Pfizer) High-fat meal decreases Cmax and AUC;\nCmax 4 to 6 h following oral dosing;\nM=Mean absolute bioavailability=43% after 250 mg oral dose;\nVd= 1772 L (after IV administration 50 mg) (suggests potentially high tissue distribution) Metabolized by CYP3A4, CYP3A5 250 mg orally twice daily;\n91% binding Pulmonary toxicity, such as interstitial lung disease, is a rare side effect associated with ALK inhibitors; most can be managed efficiently by lowering doses or interrupting treatment; crizotinib was responsible for adverse pulmonary interstitial lung disease and severe pneumonitis in a small percentage of patients (238) (239) (240); associated with ground-glass opacity predominant pattern interstitial lung disease (151)"}

{"project":"2_test","denotations":[{"id":"32778962-29174221-84130754","span":{"begin":644,"end":647},"obj":"29174221"},{"id":"32778962-30771874-84130755","span":{"begin":650,"end":653},"obj":"30771874"},{"id":"32778962-31019956-84130756","span":{"begin":656,"end":659},"obj":"31019956"},{"id":"32778962-28373069-84130757","span":{"begin":746,"end":749},"obj":"28373069"}],"text":"Crizotinib (Xalkori)\n(Pfizer) High-fat meal decreases Cmax and AUC;\nCmax 4 to 6 h following oral dosing;\nM=Mean absolute bioavailability=43% after 250 mg oral dose;\nVd= 1772 L (after IV administration 50 mg) (suggests potentially high tissue distribution) Metabolized by CYP3A4, CYP3A5 250 mg orally twice daily;\n91% binding Pulmonary toxicity, such as interstitial lung disease, is a rare side effect associated with ALK inhibitors; most can be managed efficiently by lowering doses or interrupting treatment; crizotinib was responsible for adverse pulmonary interstitial lung disease and severe pneumonitis in a small percentage of patients (238) (239) (240); associated with ground-glass opacity predominant pattern interstitial lung disease (151)"}